BCL2 and small cell lung carcinoma: Although initial attempts at targeted therapy in SCLC have been unsuccessful, several newly identified targets agents, such as anti-angiogenic strategies and Bcl-2 inhibitors, hold promise and are being tested in the ongoing clinical trials.28–30